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a b s t r a c t
We report a patient with features of Cowden syndrome (CS). A 35-year old woman has been
suffering from headache, vertigo and mild imbalance since 2 years. Examination showed
subtle mucocutaneous lesions: papillomatous papules on the gingival mucosa, a few
verrucous acral skin lesions and macrocephaly. Magnetic resonance imaging (MRI) revealed
a tumor of the left cerebellar hemisphere with ‘‘tiger-striped’’ pattern on T2-weighted image
(T2WI), typical of Lhermitte-Duclos disease (LDD) – one of the pathognomonic but infrequent
features of CS. A pathogenic de novo heterozygous PTEN mutation: c.49C>T variant has been
identiﬁed in exon 1 of the PTEN gene by sequencing.
# 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Cowden syndrome (CS) MIM 158350 is a rare, clinically
heterogeneous disorder, inherited in an autosomal dominant
manner. It is characterized by multiple hamartomatous tumors
originating from all three embryonic layers and increased risk of
different malignancies. About 80% of the cases result from
germline mutations in the tumor suppressor gene PTEN, located
on chromosome 10q22-23 [1]. The gene spans nine exons and
encodes a phosphatase amino acid protein that regulates the
cellular growth, apoptosis, migration as well as angiogenesis.* Corresponding author at: Department of Genetics, Institute of Psych
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0028-3843/# 2015 Polish Neurological Society. Published by Elsevier SThe mutations in PTEN gene cause several PTEN hamartoma
tumor syndromes (PHTSs), including Cowden, Bannayan–Riley–
Ruvalcaba, Proteus syndromes and Lhermitte-Duclos disease
[2]. Previous studies have described symptoms overlapping in
these conditions [3,4]. Lachlan et al. even suggested that
Cowden syndrome and Bannayan–Riley–Ruvalcaba syndrome
are one disease with inter- and intrafamilial clinical variability
and age-related penetrance [5]. Germline PTEN mutations have
also been found in autism spectrum disorders with macro-
cephaly [6]. Somatic mutations of the PTEN gene were identiﬁed
in various tumors, such as, in glioblastomas, melanomas,
carcinomas of endometrium, breast, prostate and thyroid [7–12].iatry and Neurology, Sobieskiego 9, 02-957 Warsaw, Poland.
umlub.pl (T. Trojanowski), zbroanna@interia.pl (A. Drelich-Zbroja),
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women, Rachel Cowden [13]. The prevalence of CS is estimated
between 1:200 000 and 1:250 000 individuals [14,15] with
predominance in Caucasians and in females [16]. There is wide
clinical variability in severity of phenotypes and individuals
with subtle features of the syndrome may remain unrecognized
[17–19]. Trichilemmomas (hamartomas of the outer sheath
epithelium of the hair follicle), papillomatous papules (benign
lesions of epithelium) on the face and oral mucosa with
cobblestone appearance on the buccal and gingival mucosa as
well as acral and plantar keratoses are pathognomonic
mucocutaneous features of CS. 99% of the patients with CS
reveal these symptoms by their third decade of life [2]. The
gastrointestinal lesions are present in 70–85% of the cases,
including polyps and glycogenic acanthosis (white plaques in
the distal esophagus consisting of glycogen-ﬁlled squamous
cells) [20,21]. Patients with CS are at increased risk to develop of
benign and malignant tumors of some organs, predominantly:
breast, thyroid, endometrium, colon and renal cells [22–26].
Previous reports described occurrence of multiple arteriovenous
malformations (AVMs) in the pelvis, liver, cervical vertebra
as well as bleeding from AVMs of the small intestine [27,28].
The clinical diagnosis of CS is based on diagnostic criteria
established by International Cowden Consortium [29].
Adult–onset Lhermitte-Duclos disease (LDD) associated
with CS, characterized by slowly growing cerebellar hamar-
toma (dysplastic gangliocytoma), was recognized to be one
of the CS pathognomonic criteria since 2004. The clinical
picture of LDD is associated with the enlarging tumor in the
posterior cranial fossa, resulting in cerebellar dysfunction and
raised intracranial pressure. Sometimes the patients complain
of headache and mild instability only, but vomiting, dysar-
thria, dysphagia, ataxia and visual disturbances may also
occur [30]. Usually LDD has insidious onset and slow
progression, although there are some reports of sudden onset
with severe clinical presentation of LDD [31]. Almost all adult
individuals with LDD had PTEN mutations [32].
Here we report a patient affected with Lherimitte-Duclos
disease – one of the PTEN hamartoma tumor syndromes
considered as phenotypic variant of CS.
2. Case presentation
A 35-year old woman was referred to our Genetic Department
with suspicion of Cowden syndrome. Magnetic resonance
imaging showed a lesion of the left cerebellar hemisphere,
with the characteristic ‘‘tiger-striped’’ appearance on T2-
weighted image (T2WI), measuring 35 mm  20 mm  25 mm
and slightly compressing fourth ventricle (Fig. 1). Initially, this
lesion has been considered as being of a vascular origin but
another radiologist who consulted the patient (ADZ) suggested
the diagnosis of CS. The tumor has not progressed to date
(Fig. 1) and has remained without surgical intervention, but
the neurosurgeons recommended MRI every 6 months.
The patient has been complaining of headache, vertigo and
mild gait imbalance since 2 years. At 26 years of age, she
underwent gynecological diagnostics due to paramenia and
ultrasonography showed bilateral ovarian cysts. She had also
nodular goiter (diagnosed by ultrasonography and ﬁne-needlebiopsy) and hypothyroidism treated to date by Euthyrox. She
has had recurrent increased blood sugar levels and needed
anti-diabetic drugs. Endoscopy, performed due to gastric
complaints, when she was 34 years old, revealed erosive
gastritis, two polyps in cardia region of stomach and multiple
white plaques in distal part of esophagus, recognized as
glycogenic acanthosis. She has been diagnosed and treated
with gastrointestinal mycosis.
The patient is the third child of non-consanguineous
parents. She has four healthy siblings and no children (Fig. 2).
There was no family history of neoplastic disorders. The
patient's mother at 47 years of age had subarachnoid
hemorrhage but no aneurysm or arteriovenous malformation
have been found in her. She was under gynecologist care
because of irregular menstruation. The father of the patient
has had right side hearing impairment and received treatment
because of the increased glycaemia.
3. Results
Physical examination of the patient showed several very small
papillomatous papules with cobblestone appearance on the
gingival mucosa, a few verrucous acral skin lesions, measuring
0.2–0.3 cm and large head circumference – 59 cm (size greater
than the 97th percentile). The neurological status was normal.
The informed consent was obtained from the molecularly
tested family members. Genomic DNA was extracted from
peripheral blood through the standardized phenol/chloroform
extraction method. The genetic study was carried out in Genetic
Diagnostic Network (Gendia, Belgium, Antwerp). Sequencing
of the promoter region and the entire coding region (exons 1–9)
and of all intron–exon boundaries as well as and the core
promoter of the PTEN gene was performed. A pathogenic
heterozygous PTEN mutation: c.49C>T variant was identiﬁed in
exon 1 of the PTEN gene by sequencing. This variant is a
nonsense mutation predicted to lead to the substitution of a
glutamine by a premature stop codon on position 17 (p.Gln17X),
resulting in a truncated PTEN protein or diminished PTEN
mRNA due to mRNA decay. This is a known change previously
reported in other patients [33] and it is classiﬁed as a pathogenic
variant according to the Mutation Database criteria.
The physical and neurological examination of the patient's
parents did not reveal any abnormality and DNA analysis
performed in them did not show the mutation found in their
affected daughter – so the mutation in the proband was a new
one (de novo mutation).
4. Discussion
The mutation in the ﬁrst exon of the PTEN gene found in the
presented case has already been identiﬁed in other patients
[33] however according to the literature most of mutations in
CS have been detected in exons 5, 7 and 8 [34]. In 40–60% of the
reported cases the mutations of the PTEN gene in CS are de
novo and our case belongs to this category.
Cowden syndrome is recognized using International Cow-
den Consortium Diagnostic Criteria [29]. The pathognomonic
mucocutaneous features of CS are observed before the third
Fig. 1 – Magnetic resonance imaging of the brain performed in November 2011 (A and B) and in February 2013 (C and D) –
Progression has not been observed. (A and C) T1-weighted axial images showing hypointense tumor of left cerebellar
hemisphere with isointense strips. (B and D) T2-weighted axial images showing hyperintense lesion with linear
hypointensity strips. Cerebellar alteration slightly compresses fourth ventricle. The ‘‘tiger-striped’’ MRI appearance of this
lesion is characteristic of Lhermitte-Duclos disease.
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patients and by the physicians. The adult onset LDD is a rare
condition associated with and pathognomonic of CS caused by
the mutations in PTEN gene. However it is worth to note that no* DNA
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Fig. 2 – Pedigree of the family. The filled symbol indicates
the affected woman (II-3) with a detected PTEN gene de
novo mutation (no mutation in PTEN gene was found in her
parents).changes of PTEN gene have been identiﬁed in children with LDD
[32]. Despite the fact that LDD progresses usually slowly, it is a
life-threatening condition, resulting in increased intracranial
pressure and neurological and sometimes visual disturbances.
Symptomatic LDD patients should undergo the surgical resec-
tion of the tumor. The regrowth of cerebellar gangliocytoma has
been observed [35], thus individuals after surgical intervention
should under radiological and neurosurgical care. The LDD is a
rare condition and its frequency in patients with CS is yet
unknown [34]. In CS patients, variable benign alterations may be
found, such as thyroid lesions (multinodular goiter, adenomas,
hamartomas), ﬁbrocystic breast disease, uterine ﬁbroids or
leiomyomas, bicornate uterus, lipomas, ﬁbromas and vascular
anomalies. Macrocephaly occurs in up to 100% of the cases [5].
Among the rarer symptoms of CS, developmental delay and
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dangerous for the patients, however, is predilection to malig-
nancies, particularly of the breast, thyroid and endometrium
cancer.
Authors of numerous studies described also high incidence
of gastrointestinal polyps of different histological type in PTEN
mutations carriers and increased risk of gastrointestinal
malignancies in them [3,4,27].
Given increased susceptibility to benign and malignant
tumors, the CS patients should be screened for cancer,
according to the National Comprehensive Cancer Network
(NCCN) guidelines [36].
The presented patient met CS criteria established by
International Cowden Consortium [30]. Her left cerebellar
hemisphere tumor was the ﬁrst ﬁnding, which could be
considered as characteristic of Lhermitte-Duclos disease
associated with CS. The macrocephaly was not noticeable
although the patient declared that she often had difﬁculty with
matching caps and hats. Mucocutaneous lesions were weakly
expressed: she noticed but has never reported them to the
physicians. The tumor has not progressed to date (Fig. 1) and
has remained without surgical intervention, but the neuro-
surgeons recommended MRI every 6 months. After establish-
ing the diagnosis of CS, a series of investigations have been
carried out. Ultrasonography showed multiple cysts in the
breast. Thyroid and endometrial ultrasonography carried out
earlier did not show any changes. The plans for near future are:
breast biopsy, colonoscopy and gastroscopy. The patient will
be screened according to NCCN guidelines [36].
The present case demonstrates the importance of genetic
testing of the affected persons and their family members in the
process of establishing or conﬁrming the diagnosis which
consequently enables clinicians to offer proper treatment,
preventive measures and genetic counseling.
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